Demand hiccup coming in Q4
– Inderes
Tämä sisältö on vain Inderes Premium -käyttäjille.
We reiterate our 7.7 EUR target price and Accumulate recommendation for Okmetic after the Q3-result. The company had a strong Q3 profitability but due to a rapid slowdown in the semiconductor market, the Q4 is likely to become a challenging quarter for the company. Nonetheless long-term fundamentals...
Inderes Premium
Tämä sisältö on vain Inderes Premium -käyttäjille.